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Abstract
This paper aims to identify problems in estimating and the interpretation of the magnitude of intervention-related change
over time or responsiveness assessed with health outcome measures. Responsiveness is a problematic construct and there
is no consensus on how to quantify the appropriate index to estimate change over time between baseline and post-test
designs. This paper gives an overview of several responsiveness indices. Thresholds for  effect size (or responsiveness
index) interpretation were introduced some thirty years ago by Cohen who standardised the difference-scores (d) with
the pooled standard deviation (d/SDpooled). However, many effect sizes (ES) have been introduced since Cohen’s original
work and in the formula of one of these ES, the mean change scores are standardised with the SD of those change scores
(d/SDchange). When health outcome questionnaires are used, this effect size is applied on a wide scale and is represented
as the Standardized Response Mean (SRM). However, its interpretation is problematic when it is used as an estimate of
magnitude of change over time and interpreted with the thresholds, set by Cohen for effect size (ES) which is based on
SDpooled . Thus, in the case of using the SRM, application of these well-known cut-off points for pooled standard
deviation units namely: ‘trivial’ (ES < .20), ‘small’ (ES  ≥.20 <. 50), ‘moderate’ (ES ≥ .50 < .80), or large (ES ≥. .80),
may lead to over- or underestimation of the magnitude of intervention-related change over time due to the correlation
between baseline and outcome assessments.  
Consequently, taking Cohen’s thresholds for granted for every version of effect size indices as estimates of intervention-
related magnitude of change, may lead to over- or underestimation of this magnitude of intervention-related change over
time.
For those researchers who use Cohen’s thresholds for SRM interpretation, this paper demonstrates a simple method to
avoid over-or underestimation.
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Introduction
Methodological problems in estimating change
in outcome with well-known measures of
quality of life or health status have become a
significant place on the research agenda in
clinical evaluation research. However, these
methodological problems seem to be relevant
in integrated care research in which the
integrated approach is compared with standard
care practice when quality of life or health
status outcome measures are used.
Furthermore, improving methods to estimate
change may contribute in the development of
evidence based practice. This article was
written because researchers in the field of
health services research seem often unaware
of the wide variety of indices that may
contribute to the understanding of an
intervention’s or programme’s effect (in
addition to its statistical significance) in terms
of health-related Quality of Life (HRQL)
outcome or health-related functional status
(HRFS). In the attempts to improve healthcareInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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delivery  with a new approach, researchers
may have the need to distinguish between
those who improved in terms of ‘small’,
‘moderate’ or ‘large’ before this new approach
will become general practice. The problem of
testing differences between the new approach-
group and a standard care group goes
together with the dilemma that with large
samples, trivial differences between these
groups maybe statistically significant. 
There is a growing recognition that assessing
an intervention’s effect should not only focus at
the statistical significance of the differences in
health outcome between the experimental care
and control group, but should also focus at the
relevance or importance of these outcomes.
Estimating the magnitude of the difference
between change scores in both groups, the
difference between mean change scores are
expressed in standard deviation units with the
effect size index (ES). To compare the
magnitude of change ∆E assessed in the
experimental group with change ∆ C assessed
in the control group the idea of effect size
between groups can be turned on its side and
applied to measurement instruments to
estimate the amount of change over time
within a group. Change over time indices are
also applied to measurement instruments to
evaluate them in terms of being sensitive to
detect change in before – after studies. In
literature on psychometrics or clinimetrics the
concept of responsiveness  was introduced to
denote the magnitude of change over time or
sensitivity to change over time. However, many
responsiveness indicators have been proposed
and resulted in numerous effect size indices
(ES). Most of the indicators agree on the
numerator (the change score between baseline
and post-treatment) but there is little
agreement on the appropriate denominator.
Since a general convention for effect size
interpretation is used for almost any ES out of
this effect size family, researchers run the risk
of overestimation or underestimation of an
intervention’s effect. This paper gives, on the
one hand, an overview (not an exhaustive
enumeration) of several responsiveness
indices that may be relevant for evaluation
research in health care. On the other hand, this
paper gives a simple solution for
underestimation or overestimation for two
widely used ES.
Health services research is heavily dependent
on valid health measures  e.g. of health-related
quality of life (HRQL) or health-related
functional status (HRFS). These concepts
have become important in the measurement of
intervention-outcome and used as comparable
outcomes in cost-effectiveness evaluation.
However, in evaluation studies quality of life
outcomes have turned out to be a
‘kaleidoscopic’ concept since no consensus
exists with regard to the meaning of the
concept in either the research community or
the clinical community. Furthermore, the
operationalization of the concept of (health-
related) quality of life is heavily dependent on
the disciplinary perspective in outcome
assessment. This lack of consensus has given
rise to the development of a myriad of
measures involving different components
whose conceptual dimensions vary.[1]
Therefore, instruments labelled as quality of
life measures “may appear as health status,
physical functioning, emotional functioning,
perceived health status, symptoms, mood,
need satisfaction, well being, and, often,
several of these at the same time”.[2] During
the last 10 to 15 years, there has been an
exponential increase in the development and
use of instruments to measure the outcomes of
medical interventions from the patient’s
perspective. A family of more than 150
instruments were identified in 75 studies; [3] in
1996, Spilker et al. catalogued nearly 215
measures in their second edition of “Quality of
Life and Pharmacoeconomics in Clinical
Trials”.[4] Since there is no consensus on the
theoretical construct of quality of life, [2, 5-8]
the universe of domains belonging to this
concept (and therefore the ongoing discussion
on the selection of items by which it is
operationalized), we prefer concepts such as
health-related functional status. Functional
status reflects the ability to perform the tasks of
daily life in physical, emotional and social
domains. There is also a growing agreement
on the components of these constructs and the
validity of their measurement; for example, by
validating these self-report measures with
evidence-based measures.[9-11] By using the
term health-related functional status (HRFS) in
this paper, we implicitly assume that a change
in health status or functioning is indirectly
related to the patient’s subjective experience of
quality of life. 
For health care administrators or other health
professionals who feel the need to measure
HRFS as an outcome in evaluation of, for
example, the effectiveness of hip-replacement
by comparing integrated care with standard
care [12], it is essential to know that the choice
of available health status instruments is related
to the methodological debate on the
psychometric properties of instruments (in
contrast to outcomes such as physiologic
measures). Consequently, this choice is also
associated with methodological issues relatingInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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to the interpretation of outcome in terms of the
magnitude of intervention-related change over
time in HRFS or the assessment of the
magnitude of differences in outcome between
experimental (e.g. managed care, transmural
care, shared care) and control groups
(standard care, usual care). 
Because improving the functional status of
patients has become a central therapeutic goal
of treatment for many diseases, it is important
that health administrators, clinicians and
researchers develop a common understanding
of:
–  what HRFS concepts mean; 
–  which measure is likely to be the most
appropriate one in the context of the
disease and the evaluation of, for
example, an interdisciplinary or
integrated approach; 
–  the methods to assess intervention-
related change (responsiveness of
outcome measures); and 
–  the methods by which a valid
interpretation of the magnitude of that
change in terms of relevance or
importance can be achieved.
In the current paper the methods to assess the
effectiveness of an intervention in terms of
change over time (responsiveness) will be
discussed since valid assessment of the
magnitude of the patients’ improvement,
deterioration and of no change seems to
become important in detecting stable,
improved and deteriorated patients-groups to
evaluate direct costs of new interventions in
the context of disease management. 
The psychometric properties of
HRFS outcome measurement tools
When the reliability and validity of health-
related functioning measures have been
established, these psychometric properties are
generally accepted conditions for use of these
measures in evaluation research. 
However, the appropriateness of the
instrument designed to measure change over
time in persons is not only determined by its
reliability and validity. Measuring change in
order to evaluate efficacy of, for example, new
care interventions requires the instrument to be
sensitive to detecting change when patients
improve in physical function after that
intervention. Over the last 15 years, this
property has become well known through the
widely used concept of responsiveness.
Responsiveness of health status measures
has been denoted as one of the ‘holy trinity’ of
necessary psychometric properties of health
status instruments: reliability, validity and
responsiveness although other researchers
classify responsiveness as longitudinal
validity.[13] To quantify responsiveness,
several effect sizes are used as estimates of
the amount of change detected with an
instrument. One of the aims of this paper is to
address some methodological issues relating
to the assessment of change over time in
health-related functional status and the
meaning of the magnitude of this change in
scores within experimental and control groups.
Traditionally, the many generations of
researchers who have evaluated the efficacy of
care-related interventions, base their decisions
on the statistical significance of the within-
group (intervention-related) change over time
or any statistically significant difference in
change from repeated measurements between
experimental (care) and control groups (with
the underlying hypothesis that the
experimental group should show a higher
mean change in terms of improvement
compared to the control group).[12, 14] In
some cases, investigators eager for results are
likely to detect a statistically significant (but
very small) change in scores related to the
intervention, simply due to large sample size.
Consequently, even if change which is
statistically significant, though trivial in
magnitude, is detected, the p < 0.05 doctrine
unwittingly pushes the question of how
meaningful, important, relevant, or substantial
the change is into the background.
Significance tests support the decision as to
whether the change is due to chance
fluctuation or can be functionally related to
(medical) intervention. The observed statistical
significance does not indicate the magnitude of
change. In spite of this, some researchers
implicitly suggest that smaller p-values
represent larger, and thus more ‘relevant’,
effects.[15] 
Against this background, the objectives of this
paper can be formulated in terms of the
following topics:
–  Responsiveness is a construct that is
used with different theoretical
definitions and with a wide variety of
operationalisations by effect size
indices.
–  How comparable are different
operationalisations of effect sizes (ES)
when outcome is interpreted as ‘trivial’
(ES < .20), ‘small’ (ES ≥ .20 < .50),
‘moderate’ (ES ≥ .50 < .80), or ‘large’International Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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(ES ≥ .80) according to the well-known
thresholds of Cohen?[16]
–  How concordant are the effect sizes,
labelled by the researcher as ‘trivial’,
‘small’, ‘moderate’, or as ‘large’ change
in a domain of health-related function
with the patient’s perception of change
in the same domain signified with the
same qualitative terms?
Responsiveness, a problematic
construct 
To give greater meaning to the interpretation of
the amount of change in scores on health-
related functional status instruments, the
concept of responsiveness was introduced in
publications. For evaluation studies, the
usefulness of a HRFS- instrument depends on
its ability to detect a change that is clinically
meaningful. Clinically meaningful refers to a
change that justifies alteration in management
of the disease or to a change that indicates the
efficacy of an innovative type of intervention in
domains of HRFS. Responsive measures
discriminate between trivial and substantial
changes within groups and consequently,
show the difference in change between those
groups. Thus, the term responsiveness is used
as an indicator of the instrument’s sensitivity to
change, as well as an indicator of the
magnitude of intervention-related change over
time. The term responsiveness, however, is a
confusing one for the beginner who encounters
it in the literature, since papers addressing
intervention-related change in terms of HRFS
may refer to a varying composite of aspects.
As appears from a selection of scientific
papers, the term responsiveness is used as an
operational definition of:
–  ‘An indicator of the sensitivity of an
instrument to detect change over time’
[17-22] or even refer to the extent to
which a measure is sensitive to real
change [23]; 
–  ‘statistically significant change in an
experimental group in which change
should be present’ [24]; 
–  ‘an indicator of the magnitude of
treatment-related change’ [20-22, 25-
35, 35, 35-56]; 
–  ‘a measure of clinically relevant
change in health’ [57, 58], although
some investigators prefer the term
‘clinically significant change’ [59, 60]. 
Qualitative terms such as ‘clinically important’
need at least a golden standard. However,
such a standard is not available for HRFS
measures. An substitute that is often used for a
golden standard for HRFS is an external
criterion. The blinded observation of a health
professional can be used as an external
criterion for justifying the interpretation in terms
of clinically relevant or important change in
HRFS. Another external criterion or yardstick
for the interpretation of changes in HRFS is the
patient’s perception of the importance of
change after (for example) a specific
intervention.
Husted et al. [61] distinguished internal
responsiveness from external responsiveness
by defining internal responsiveness as the
ability of a measure to detect change over
time, whereas external responsiveness was
defined as the extent to which change in a
measure relates to corresponding change in a
reference measure [11, 62, 63]. Despite this
clarification of the concept of responsiveness
by this recently published classification, the
assessment of change in HRFS over time in
evaluation research is quantified using a
variety of approaches. For the sake of clarity,
we will therefore in this paper use the concepts
in the following meaning:
–  responsiveness: the psychometric
property of a measurement instrument,
namely its sensitivity to detect
difference between two points in time
(change over time) within groups;
–  meaningful or relevant difference: the
amount of change in scores or the
magnitude of change within and
between groups, according to
statistical or other quantitative criteria
(e.g. effect size indices);
–  clinically relevant or clinically important
change in scores on a health-related
functional status measure as the
magnitude of change that is linked to
an external criterion of relevance.
The purpose of a study and its study design
may require different psychometric properties
of the outcome measure. Consequently, the
measure must either have the property of
being able to detect differences between
subjects at a single point in time (discriminative
instruments) i.e. the ability to differentiate
between groups ‘who have a better HRFS and
those who have a worse HRFS ‘ [53, 64, 65].
Other studies may require the instrument’s
ability to detect change over time within
subjects (evaluative instruments).[66-68]
Consequently, in randomised clinical trials
(RCT) or quasi-experimental designs, HRFS-
instruments should have both properties,
namely: 1. the ability to reliably estimateInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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change between baseline and post-test within
an experimental and a control group, and 2.
the ability to estimate the difference in change
over time by comparing the average change
assessed in e.g. patients receiving standard
care and in patients receiving the new care
intervention in order to determine intervention-
related effect, when it is hypothesised that
subjects assigned to the care innovation group
are expected to change (on the average) more
than those in the control group do. 
Responsiveness and the
instrument’s scope: generic
versus specific measures
An important criterion for choosing an
instrument in order to detect change in HRFS
is its generic or disease-specific scope, which
will depend on the objectives of the specific
study. Generic health status measures seek a
broad perspective that is not specifically
related to the restricted scope of the HRFS of a
specific disease. Therefore, generic measures
allow investigators to compare health status
across different diseases and interventions.
[69] Generic measures are health-related to
the extent that disease, injury, treatment,
intervention, or policy [70] influences them.
Disease-specific measures focus on the
disease being studied, allowing greater
sensitivity to intervention-related change
compared to generic measures. The
responsiveness of a health status instrument is
an important issue in the decision to use
disease-specific or generic measures of
health-related functional state. For example,
for those cases in which therapeutic effects are
likely to be modest and undramatic, [12, 19,
71] a better sensitivity to change over time of
an instrument is a necessary condition. In
health services research, hypothesising
statistically significant change over time and
more substantial change (improvement) in
patients assigned to the experimental group of
managed, shared or integrated care, effects
are not likely to be large or impressive. Using
disease-specific outcome measures gives an
opportunity to tap more precisely intervention-
related improvement in domains of health,
which may have been deteriorated due to the
disease where generic measures contain items
that are not likely to be linked to domains of
health status that may change due to the
disease or handicap of the patients in the
study. Although the question of whether
instruments, that are tailored to the disease,
are superior to measures of general function in
terms of sensitivity to change, has not been
settled definitely, a growing number of studies
indicate that disease-specific measures seem
to be more responsive than generic
measures.[36, 42, 47, 51, 72-76]
Effect size (ES) as indicator of
responsiveness
Mean differences in outcomes between
baseline and post-intervention of a test can be
standardised to quantify a care intervention’s
effect in units of standard deviation (SD).
Consequently, standardising mean change
over time with a standard deviation allows
comparison of a particular intervention’s
different outcomes, independent of the
measuring units. The resulting statistical
measure is known as effect size  (ES) index. In
many evaluation studies, standardised change
over time in HRFS (ES) is used in comparisons
of groups who were treated differently. This
method of expressing change scores in a so-
called effect size index seems to be an
appropriate method to estimate the magnitude
of change over time in before-after study
designs. 
The effect size index tells us something very
different from the p-value, which indicates the
obtained probability of a Type I error in a test
of statistical significance. If a p-value is
annotated as statistically significant, rejecting
the null-hypothesis does not imply that the
effect was important in any way nor does a
non-significant p-value indicate a trivial result.
[77-80] Criticism of statistical hypothesis
testing has a long history, [81] and even Jacob
Cohen [15, 82] “played a prominent role in the
anti-hypothesis-testing charge".[83] The
adoption of a fixed level of significance may
lead to the situation in which two researchers
obtain identical intervention effects but obtain
different p-values (0.04 and 0.06) due to the
effect of (slightly) different sample sizes
leading to different decisions. Thus, p-values
are confounded by the joint influence of
sample size and the effect size [84] and make
the rejection of the null-hypothesis not very
informative. Another criticism of null hypothesis
testing is that it is foolish to ask: ‘Are the
effects of A and B different?’ "They are always
different- in some decimal place- for any A and
B".[85] Since then, quantitative investigators in
medical and social sciences have proposed a
variety of supplementary effect size indices,
some of which we will clarify. Reporting effect
sizes without appropriate statistical tests and
associated p values is misleading and
potentially dangerous if the number of
observations that is required to detect a
difference has not been estimated by means of
a power analysis. Effect size statistics should
be provided to supplement statistical testingInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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(not as a substitute for it), and only when the
outcome is sufficiently extreme from what
would have been expected on the basis of
chance (p <α).
It should be noted that during the debate on
‘significance testing’, several vocal leaders in
psychology and education research called for
the universal reporting and interpretation of
empirically produced effect sizes [86, 87].
There are myriad estimates of effect size out of
which the researcher can make a choice [88]
and the question arises as to which of the
effect size measures ‘that could be summoned
up for a given problem should a researcher
report?’ [83, 84] The most elegant solution for
this problem would seem to be for authors to
include the sufficient statistics so that every
reader can compute whichever effect size
index they believe is best suited to the
situation. Table 1. gives an overview of
responsiveness measures in repeated
measurement study designs.
Table 1 Formulas for responsiveness measures for change over time (Within-group standardised mean change)
Paired t statistic 8 1 - 8 2
________ 
  SE*
Effect size (1) 8 1 - 8 2
__________
SDpooled ** 
Effect size (2) 8 1 - 8 2
__________
SD baseline scores
Effect size (3) (8 1 - 8 2) treated subjects – (8 1 - 8 2) controls
_____________________________________________
SD pooled baseline
Standardised Response Mean (1) 8 1 - 8 2
_________
SD change scores
Standardised Response Mean (2) 8 1 - 8 2 (improved subjects)
__________________________
SDchange scores (improved subjects)
Standardised effect size 8 1 - 8 2 (improved subjects)
___________________________
SDbaseline (improved subjects)
Responsiveness index (1) M.C.I.D***
___________
SDchange scores (stable subjects)
Responsiveness index (2) 8 1 - 8 2
__________
SDbaseline (stable subjects)
Responsiveness index (3) 8 1 - 8 2
____________________________
SDchange scores (stable subjects)International Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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Responsiveness coefficient  σ
2
(81-82)
______
σ
2 
(81-82) + σ
2 error 
Normalized ratio 8 1 - 8 2 (improved subjects)
____________________________
SDbaseline (stable subjects)
Relative efficiency statistic
Relative efficacy index ****
(t- statistic measure 1/  t-statistic measure 2 )
2
(Esp/ESpbest)
2 x 100
* SE = standard error of the difference
 
       (Sdbaseline)
2+ (Sdoutcome)
2
** where pooled SD =  √ 
___________________________________ for: Nbaseline  = Noutcome
2
*** Minimal Clinically Important Difference according to external criterion (i.e. the difference in change score
between those who perceived no change and those who perceived little change) which is considered to be the
minimal difference in change over time that patient’s perceive as meaningful).
**** Magnitude of change over time is estimated for each scale by dividing the mean change by the
pooled variance of change, according to Cohen {154} denoted as ESp. This relative efficacy
statistic is computed by squaring the ratio obtained by dividing each scale ESp (numerator) by the
scale having the largest ESp (denominator). This statistic is then expressed as a percentage with
respect to the best measure
Effect size: a problematic statistic
For those researchers who are not conversant
with this method of estimating the amount of
change over time it is essential to know that in
the last decade various critical comments
about Cohen’s work [16] have been made.
These include:
–  there is no consensus on the
‘theoretical’ meaning, or the
conceptualisation of the effect size as
an outcome variable;
–  there is no consensus on the
mathematical way to determine the
magnitude of the difference between
scores gained on two different
occasions: researchers classify the
extent of responsiveness and
magnitude with effect sizes using
several standard deviations (See table
1);
–  threshold values for ‘trivial’ (<.20),
‘small’ (≥ .20< .50), ‘moderate’ (≥ 50<
.80) and ‘large’(≥ .80) effects only
apply to Effect size 1 in table 1.
How to give meaning to the magnitude of
change 
Regarding the use of the notion of effect size in
HRFS research, several researchers have
claimed that without an external criterion, the
estimated amount of change measured by the
effect size index can be denoted as clinically
important change.[20, 21, 57, 58, 89] Other
researchers assume that an effect size,
estimated within a group of subjects,
expresses the measure’s ability to detect
change over time (due to an experimental
intervention) [17-22, 57, 72] without claiming
that their effect size indicates that the
instrument is sensitive or responsive toInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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clinically relevant changes in the patients’
perceived health. When a HRFS instrument is
used as an outcome measure, and the amount
of change estimated with change scores (or
quantified by an effect size) is defined as
clinically relevant, the following question
logically arises: ‘What is meant by a clinically
relevant change?’ [90, 91] Because patients
and health professionals differ in the
preferences or perceived relevance that they
assign to particular aspects belonging to
domains of health-related functional status,
several authors have incorporated these
perceptions or preferences into health status
instruments’ items and scales [5, 75, 89, 90,
92-95] to give more significance to the term
‘relevant’. In this paper we address the
methodological problems of quantifying change
over time with effect size indices and the risks
of overestimation and underestimation
according to widely used thresholds introduced
some 30 years ago.[16]
How to quantify change in terms of
effect size
Many evaluation studies have been conducted
that use different methods to estimate
magnitude of change over time in terms of
Effect Size (ES). These have indicated that
there is no convincing evidence that either
method offers any apparent advantages.[6, 74]
The literature shows that numerous
quantitative indices belonging to the family of
effect sizes (ES) [88] have been developed.
However, there is no consensus on how to
declare a difference in terms of standard
deviation units. The interpretation of the effect
size is determined by the choice of the
standard deviation used to standardise the
mean change over time and, related to that, by
the ready adoption of the interpretation
guideline as set by Cohen.[16]
 Several effect
size indices are used in HFRS and quality of
life research, which have in common that X1 -
X2 is divided by a standard deviation. The
researcher’s decision as to which SD he will
take is either a well-considered choice or one
which is copied from well-reputed colleagues
and has no further justification. However, in
giving meaning to standardised mean change
in terms of ‘trivial’, ‘small’, ‘moderate’, or ‘large’
effects using the thresholds that Cohen [16]
provided us with some thirty years ago, it
seems to have been forgotten that these cut-
off points were calculated with the pooled
standard deviation (SDP). Consequently,
applying these thresholds for mean change
scores standardised with the standard
deviation of the change scores (Xt-1 - Xt-2
/SDX1-X2 ), which is not equal to the pooled
standard deviation (SDP), may lead to over- or
underestimates of effects.
For his effect size (mean baseline scores
minus mean follow-up scores, divided by the
pooled standard deviation) Cohen came up
with conventions for those values that
constitute a ‘trivial’ (ES < .20), ‘small’ (ES ≥ 20
< .50), ‘medium’ (ES ≥ .50 < .80), and a ‘large’
effect (ES ≥ 80). However, for each of the
effect size and responsiveness indices from
table 1 (except: T-Test, Normalized ratio, and
relative- and efficacy indices), these thresholds
are used indiscriminately, which may have
contributed to the confusion in this area. [61] 
Effect size interpretation: the threat of
internal and external validity of (quasi)
experimental research by overestimation
or underestimation 
In the practice of health-related quality of life
research, most researchers remain primarily
interested in the statistical significance of the
change in health-related functional status or
quality of life in pre post designs. In
combination with, e.g., the T-test approach,
substantial effects can be detected [96-98] with
an estimate of effect size. If a p-value is
annotated as statistically significant, rejecting
the null hypothesis does not imply an effect of
important magnitude; likewise, a non-
significant p-value does not indicate a trivial
result, [77-80] although some researchers
implicitly deem more important those results
with smaller p-values.
In the last decade, however, a growing number
of longitudinal intervention studies are
focussed on questions like “If the change
between baseline and outcome is statistically
significant, what can we say about the
magnitude (or amount) of change over time
that has been detected? Can we interpret this
difference in terms of an important difference
or as a relevant (substantial) change?” To
answer these questions, the responsiveness,
i.e. the ability of quality of life outcome
measures to detect change over time, has
become crucial in the past decade. However,
the responsiveness estimation is neglected in
many evaluation studies in which it could give
information on the importance of change due
to intervention-related effects supplementary to
the statistical significance of change over time
(e.g. before and after intervention).[99, 100]
Reporting effect sizes without appropriate
statistical tests and associated p-values is
misleading and potentially dangerous when the
number of observations that is required to
detect a difference has not been estimated
with a power analysis. Effect size statisticInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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should be provided to supplement (not as a
substitute for) statistical testing, and only then,
when the outcome is sufficiently extreme from
what would have been expected on the basis
of chance (p < α).
Noteworthy in this respect is that in the field of
psychological research, editorial policy
indicates that “until there is a real impediment
to doing so, authors should routinely present
an effect size estimate along with the outcome
of a significance test”.[84, 86, 87]
Table 1 shows that several quantitative indices
have been developed that belong to the family
of effect sizes (standardized differences) each
calculated with a different denominator in the
(X1 – X2 /SD) formula, for example, the SD
of stable subjects, the SD of the baseline
assessment, the SD of the observed change
score (improved, stable subjects) etc..
Obviously, there is no consensus on how to
declare a difference in terms of standard
deviation units. Only in a small number of
publications is this lack of consensus on the
most appropriate effect size indicator signalled.
[13, 90, 101-104]
Despite the fact that different opinions exist on
the method to estimate magnitude of difference
between groups or the magnitude of change
within groups, researchers use the straitjacket
of thresholds Cohen provided us with some 30
years ago.[16] However, these thresholds are
taken for granted by many researchers for
every version of effect size index. With regard
to the correct use and interpretation of effect
size indices as estimates of intervention-
related magnitude of change, we must revisit
some basic assumptions: 
–  the ES is developed and elaborated by
Cohen to estimate power or the
necessary sample size to detect
relevant change with the basic
principle of independent, equal size
samples with common within-
population standard deviation σ;
–  in the case that this ES is used to
calculate the sample size needed to
detect change in paired samples or in
a repeated measurement-design it
must be adjusted for correct use of
Cohen’s power tables and sample size
tables. However, this adjusted ES
cannot be interpreted with Cohen’s
thresholds for effect size interpretation
in evaluation research;
Effect Size estimation with
independent (treatment vs.
Control) and dependent
observations (repeated
measurement)
Independent samples
Cohen represented the effect size (ES) on
some dependent or outcome measure used in
an experiment in terms of the difference (using
the symbol d’ to denote this ES) between the
treatment and control group expressed in units
of common within-population standard
deviation (in samples this standard deviation is
estimated with the pooled standard deviation)
as follows:
[Formula A]
With this estimate of effect size, after analysing
a wide sampling of behavioural research,
Cohen developed his rules of thumb and
reported that effect of .8 σ being on the large
end of the range, .5 σ  was the medium, and .2
σ was at the small end of the range.[105] 
Dependent samples or paired
observations
The difference or change in matched
observations within subjects is standardised by
the common within-population σ, according to
Cohen’s [16] p.13., but due to the removal of
the variation in many extraneous
characteristics of the subjects, the index must
be adjusted [16]), dividing d’ by √ (1-r ). Cohen
used the symbol d to denote this adjusted ES
(in evaluation research often labelled as
Standardized Response Mean). 
[Formula B]
d’ = effect size for independent samples
d = adjusted effect size
r =correlation between baseline and outcome
This √(1-r) – correction of the denominator of
formula A is necessary for a proper use of
power and sample size tables since these
assume 2(n-1) degrees of freedom where, in
the case of paired observations, only n-1 are
actually available.[16] This consequence for
power and sample size estimation is
something different from the use of the effect
size d in evaluating efficacy of a new
intervention in terms of amount of change inInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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health status, which was not the aim of
Cohen’s work. 
Overestimation or underestimation of
effect by using Cohen’s thresholds for
SRM 
When effect sizes are calculated as the
standardized difference in mean score to
evaluate the magnitude of difference in HFRS,
for example, between an intervention group
(interdisciplinary or integrated care and a
control group, formula [A] should be used. The
effect size can be calculated by pooling the
estimates (pooled standard deviation) derived
from sample data. In contrast to this
independent sample case, effect sizes are also
used in evaluation studies (pre- post study
designs) as estimates of the responsiveness or
change over time within groups. Effect sizes
are also in these study designs used to give
meaning to change over time in terms of ‘trivial’
(ES < .20), ‘small’ (ES ≥ .20 < .50) ,’moderate’
(ES ≥ .50 < .80) or ‘large’ (ES ≥ .80) change.
Cohen [16] introduced this ‘matched pairs’
effect size, which was later renamed the
standardised response mean (SRM) by Liang
et al. [106] to avoid confusion concerning other
effect size indices. However, several
researchers seem to have adopted the idea
that every standardised difference is subject to
Cohen’s definitions of trivial, small, moderate
and large effect. Such a belief could lead to
misinterpretations in studies focussing on
intervention-related outcome in paired samples
since these cut-off points of the magnitude of
the difference were not established as a rule of
thumb with the effect size d (dependent
samples) but with the index d’ (independent
samples). Thus we argue that Cohen’s
thresholds are based on the assumption of
common within-standard deviation (with
matched pairs sample data we use the raw
within-group pooled SD), resulting in an effect
size we annotate as ESP. Consequently, in
matched pairs studies these thresholds cannot
be used interchangeably for the SRM due to
the role of the correlation between repeated
measures or between scores from paired
samples. In this part of the article the attention
is focussed on the standardized change in
mean score between two points in time within
a single group, estimated with the within-group
effect size. In relation to the use of Cohen’s
rule of thumb for effect size interpretation, we
evaluate the consequences of the calibration of
the SRM with the ESP and the role of the
correlation between pre and post test scores.
To investigate how serious discrepancies can
appear in effect size interpretation we first
elaborate a theoretical example and used a
sample of studies to evaluate the seriousness
of these differences in practice. To evaluate
the seriousness of the discrepancies between
SRM and ESP, the correlation of the subject’s
repeated measurements was needed.
Empirical data were collected for the purpose
of secondary analysis to draw conclusions in
terms of the relative size of the SRM to the
ESP in relation to the size of the correlation.
Applying Cohen’s thresholds (which are based
on the pooled estimate of effect) to interpret
the SRM on the one hand may lead to similar
results or subtle and trivial differences, but on
the other hand also to meaningful shifts in
classification of the amount of estimated
change. In this article we analysed 148 SRMs
interpreted using Cohen’s rule of thumb and
compared these SRMs with Cohen’s ESP
calculated with the same data. Furthermore,
we calculated for the range of the correlation
coefficient (r) 0.01 to 0.99 the SRM adjusted
for Cohen’s cut-off points 0.20, 0.50 and 0.80
of the pooled effect size.
To study the consequences of the impact of
the association or correlation between
repeated measures, we restrict the analysis to
two effect size indices suitable for the
evaluation and interpretation of magnitude of
change over time (or responsiveness) within
one group, namely the SRM and the ESP.
[Formula C]
The ESP introduced by Cohen was made
comparable to the SRM where the ( SDX-change
score ), is used as the denominator in which, as
we will demonstrate below, the correlation
between baseline and outcome scores is
involved.
The SRM is the ratio between the mean
change score and the variability (the standard
deviation) of that change score within the same
group. 
[Formula D]
One of our purposes was to get an indication
of how the SRM varies in accordance with the
size of the correlation between pre and post
test scores when the correct pooled effect size
estimate is used. An example may illustrate the
role of r, the correlation of a person’s health
status measurements over time: International Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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In a study in which the outcome of an
intervention was evaluated with a HRFS
measure, and in the case of improvement, a
lower mean score after intervention was
hypothesised. The investigator finds at
baseline a mean score of 11.12 with a
standard deviation of 4.43 and a mean score of
9.16 (SD: 4.88) at follow up. The estimate of
the common within-standard deviation, which
is the square root of (SDbaseline)
2+ (SDoutcome)
2
/2), thus 4.66, and the pooled effect size d’
(ESP) is then calculated as follows 0.42 (11.12
– 9.16 /4.66). Before we compare the ESP and
SRM in relation to the correlation between
repeated measurements, we must solve the
problem of the equation of both formulas C and
D. According to Cohen, the difference between
means for dependent samples is standardised
by a value “which is √2 (1-r) as large as would
be the case were they independent”. [16]
From equation A4 in the appendix, (d’/√2) /
√(1-r) is equivalent to the SRM and
alternatively SRM * √ 2 * √(1-r) is equivalent to
d’ and both indices will vary with the size of r .
In table 2 we have elaborated the hypothetical
example in which this effect size d’ (ESP ) =
0.42, is transformed into the SRM for a series
of values of r. Both effect sizes are equal in the
case that r = 0.50): ESP = (0.42/√2) / √(1-0.50)
= SRM, and the SRM for r .50 is then
(0.42/1.41) / 0.71 = 0.42. In table 2 it is shown
that the SRM gets larger for larger values of r.
For example, an effect size of 0.42 indicating ‘
small effect’ corresponds with a ‘medium
effect’ (SRM = 0.50) if the correlation between
the repeated measurements is approximately
.64. This small effect estimated with the ESP
corresponds with a ‘large effect’ (SRM  ≥ .80) if
this correlation is approximately .86. 
Table 2. The conversion of an effect size calculated with the pooled SD (ESP ) of 0.42 into a SRM with correlation coefficients
ranging from .00 - .90
Corr. .00 0.10 .20 .30 .40 .50 .60 .65 .70 .80 .86 .90
(.42/√2
 √(1-r)
.30 .31 .33 .36 .38 .42 .47 .50 .54 .66 .79 .94
If we take Cohen’s original work [16] as being
valid, we will have to rectify interpretations of
the meaning of the estimated magnitude
according to the results from this analyses.  In
previous work we published two  studies [55,
71] in which 40 Standardised Response Mean
indices were interpreted according to Cohen’s
thresholds for pooled estimates of standard
deviation (ESp) out of which 20 turned out to
be overestimations or underestimations of
intervention-related effect. (Table 3). 
Table 3 . Comparison of four Standardised Response Means calibrated into Cohen’s pooled effect size index (ESp).
Effect Size d’ (ESp)
Trivial Small Moderate Large
SRM 0 -<.20 ≥.20- <.50 ≥.50 - <.80 ≥.80
Trivial 2
Small 3 4
Moderate 9 8
Large 8 6
In another study [107] we analysed this
problem using results from other researchers.
This secondary analysis of data from other
studies revealed that 23% of the estimated
effect sizes did not fall in the same magnitude
of change category according to the Cohen’s
thresholds table 4.
Table 4 Similarities and differences between the Standardised Response Mean (SRM) and pooled effect size d’ (ESP)
interpreted using Cohen’s thresholds (N=148)
ESpooled ES < .20 ES ≥ .20< .50 ES ≥ 50< .80 ES ≥ .80 Total
Trivial effect Small effect Medium effect Large effectInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
This article is published in a peer reviewed section of International Journal of Integrated Care 12
SRM
< .20 43 2 45
≥ .20 < .50 6 35 2 43
≥ 50 < .80 11 13 1 25
≥ .80 12 23 35
Total 49 48 27 24 148
SRM indices interpreted by authors according to Cohen’s thresholds for ESpooled 
To avoid invalid interpretations in the
evaluation of responsiveness with SRM index
we have, for every value of the correlation
between baseline and follow-up score,
calculated the corresponding ESP 's for
Cohen’s thresholds of .20 = small, .50 =
medium, and .80 = large. Indices that lie within
the interval that corresponds with these
thresholds are not depicted. To classify the
magnitude of change estimated with the SRM
more precisely, this effect size index is
adjusted for every value of the correlation
coefficient (r) between baseline and follow-up
assessments and brought into line with
Cohen’s thresholds for effect size. Figure 1
shows that SRM’ s of 0.20, 0.50 and 0.80,
don’t deviate after calibration with Cohen’s ESP
taken as the original standard, when r =.50.
However, a SRM of 0.20 must be tagged as
trivial effect as long as the correlation
coefficient ranges from r =.01 to r =.49. With
large corresponding correlation coefficients (r
= .92) a small SRM of 0.20 must be tagged as
moderate (.20/√2 / √1- .92 = .50) or (r = .97)
large (.20/√2 / √1-.97 = .80). The class
midpoint 0.35 of the ‘small effect’ range of
effect (not depicted) has to be classified as
moderate or large effect with correlation
coefficients of 0.76 (.35/√2 / √1-.76 = .50) and
0.91 (.35/√2 / √1-.91 = .80) respectively.
SRM’s of 0.80 has to be tagged as ‘moderate’
effect (ES = 0.58 - 0.79) if the correlation
ranges from r = 0.01 to 0.49. The SRM ≥ 0.80
cannot drop below the cut-off points of small
and trivial ES due to the correlation magnitude
between baseline and outcome
measurements. ‘Moderate’ effect (SRM = 0.50)
must be tagged as ‘small’ if the correlation
between repeated measures is below 0.49 and
has to be classified as ‘large’  (ES=≥ .80) in
case of r = .81. The class midpoint 0.65 (not
depicted) of the ‘moderate effect’ range of
effect must be valued as ‘small’ with a r = 0.14
(.65/√2/√1-.14 = .49).
In contrast with the fixed threshold values .20,
.50 and .80 in figure 1, in the analysis of 148
effect size estimates from which the correlation
of a person’s health status measurements over
time was calculated, we found SRM values
ranging from 0.04 to 2.42.[107] Correlation
coefficients ranged from .08 to 0.89 and 70%
of the 148 coefficients were larger than 0.50.
Overestimates of effect size  are easily
estimated. For example: a SRM of 0.85
interpreted by the researcher as large effect,
changed into a moderate effect according to
Cohen’s thresholds, due to a correlation of
0.12 between repeated measurements.
Figure 1 Cohen’s threshold’s for effect size SRM corrected for the size of the correllation coefficent between repeated
measurementsInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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Conclusion - Discussion
Thus, the SRM interpretation of effect
magnitude with the thresholds Cohen with the
ESp calculated on the same data
(transformation of the same mean change over
time into units of pooled standard deviation)
may result in dramatic differences (23 - 50% of
the SRM indices are overestimated).
Unfortunately, we still have no algorithm for
effect size indices calculated with the standard
deviation from baseline scores or from change
scores in stable subjects according to an
external criterion. Furthermore, even in a
situation where we are able to reliably interpret
effect size, we cannot differentiate between a
‘large’ and ‘very large’ effect since the cut-off
point for large has a theoretical range from ES
> .80 to infinite. However, Hopkins’ [108]
Likert-scale approach is able to give meaning
to the extension of the scale to the level above
large for Cohen’s effect size statistic: ES = 0 -
< .20 trivial effect; ES = ≥ .20 - < .60 small
effect; ES = ≥.60 < 1.20 moderate effect; ES
>1.20 - < 2.0 large effect; ES ≥ 2.0 - < 4.0 very
large and ES ≥ 4.0 - ∞ is considered to be
‘nearly perfect’. In addition to thresholds for
effect magnitudes, Hopkins elaborated
Cohen’s thresholds for correlation coefficients,
relative risks and odds ratio. Despite this
promising attempt to proceed with a more
complete scale of effect magnitude, further
research will need to provide empirical
evidence for the external validity of this new
rule of thumb for effect size interpretation
irrespective of health status measure and
research designs. 
Ever since Jacob Cohen wrote his well-known
book [16], the effect size has been a
problematic parameter in evaluation research,
and several promising alternatives (for
example, the “Reliable Change Index”), have
been developed [109], improved and
criticised.[35; 110-113] In future studies
statistical computer programmes may be able
to give the researcher additional information on
some intervention effect indices
(notwithstanding the fact that no consensus
exists on a method for signifying the magnitude
of change within and between experimental
and control groups that is meaningful in
particular intervention contexts). Nevertheless,
implementing effect sizes standard in the
representation of statistical results may require
researchers to change long-held patterns of
behaviour.
The values used in effect size classification for
difference between means as small, medium,
and large was arbitrary but seemed
reasonable, Cohen stated some 30 years ago.
In the debate over which standardizing unit of
the difference one should take in a within-
group situation, we propose that estimating the
magnitude of change by using either the SD of
the change score or the pooled SD is
preferable to the use of the SD at baseline as
proposed by Kazis et al.[114], although the
SRM must be adjusted to make correct use of
Cohen’s thresholds when magnitude of change
over time is estimated in evaluation research.
These thresholds of Cohen are now being
cited without distinguishing between the unit by
which the assessed change over time is
standardised. This is surprising since there is
unequivocally no doubt that his rule of thumb
was derived from the pooled SD as the
estimate of the common within variance.
Moreover, routine action in calculating effect
sizes may have led to a reduced awareness of
factors originally considered only in the
calculation of power and sample size. ForInternational Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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instance, the calculation of power of the
detected change or difference without using
the information of r can lead to the wrong
inferences.[16]
In evaluation research on treatment-related
quality of life, researchers seem to overlook
the fact that, in assessing change over time
within one subject, the experimental technique
of 'self-matching' reduces the proportion of the
total variance due to extraneous variables not
related to the treatment or intervention per
se.[115]
We may conclude that the rule of thumb
proposed by Cohen can induce differences in
the interpretation of the size of estimated
effects. At present it does not appear to us that
a single set of rules that is unequivocal or
normative at some level is available. We have
begun to explore alternative methods in effect
size estimation and have assessed the
interrelation between two effect sizes as
estimates of magnitude of change over time
within groups.
As we have demonstrated, errors can easily be
made and different interpretations of the
magnitude of detected change may occur. In
analysing the data from our sample of
published studies on change over time in
health-related quality of life, we saw
meaningful shifts in magnitude of detected
change in relation to the size of the correlation
between pre- and posttest scores. In this
article we have attempted to draw the attention
to the problem of over- or underestimation of
effect sizes when the Standardized Response
Mean is used. Studies in which the mean
change over time is standardized with the
SDbaseline according to Kazis et al. [114] should
report the ESp to show that the results were
not dependent on the choice of denominator in
the d-index formula. 
Due to their increasing appearance, it is
important that all aspects of estimating the
magnitude of change be inspected. One of
these aspects is the consequence of the
hidden role of the correlation coefficient
between repeated measurements, which
increases the risk of incorrect conclusions.
This initial effort may provide a moderate step
toward the development of a precise and
useful index in quality of life assessment in
clinical trials.
Recommendations for practice and research
As long as no consensus is reached on
standards for evaluating, using and interpreting
effect size estimates of intervention-related
change in evaluation research, there is an
important need to develop uniform and widely
accepted criteria to give meaning to the size of
an effect. This lack of precision is not only
relevant when evaluating intervention-related
change within and between groups, but, even
more important, also in the estimation of power
in the planning phase of a trial. Standardisation
of effect size interpretation needs reference
ranges of health-related functional status
assessed with population surveys.
Furthermore, longitudinal research is needed
to discriminate between changes in HRFS over
time in a sample drawn from the general
population, with change in a sub-sample of
chronically ill patients. In other words, with
knowledge about a reference range of an
indicator of health-related functional status in
the general population, we can recognise that
there are differences. Furthermore, with a
longitudinally assessed estimate of
autonomous change in the same sample, we
will be able to better understand the
meaningfulness of intervention-related effects.
In studies on the measurement of health-
related quality of life and HRFS, effect sizes
(ES) have been used as surrogates for
clinically relevant change when change over
time in outcome was substantial. However, ES
do not provide a complete understanding of the
meaningfulness of the observed change.
Patients have to perceive a change in the
performance of daily activities in order to rate
the direction and degree of change; moreover,
even when this perceived change is small in
magnitude, it may still be perceived as a
significant one by the patient.  According to
Osoba, [116] the significance of change as
perceived by the subject ‘should be of
paramount consideration’ in future attempts to
define the meaningfulness of change in HRFS
or health-related quality of life. The
development of multi-item transition measures
may cover change in the relevant underlying
domain more representatively.[107, 117]
Therefore, we suggest that measures that
assess more concrete aspects of the patient’s
HRFS will provide greater accordance between
serial and transition measures of change.
However, when a patient rates a reduction in
(for example) difficulty in climbing stairs, as
‘large’, it does not necessarily imply that a
patient will view this subjectively significant
change as being important.  Future areas of
research aimed at quantification of meaningful
change in HRFS should also include the
importance patients assign to that change,International Journal of Integrated Care - Vol.2, December 2002 - ISSN 1568-4156 - www.ijic.org
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even if it is experienced as being small. One
piece of research has produced examples that
seem promising extensions of transition
questions. In this approach, the respondent
rates the direction and the degree of perceived
change by a assigning a value that has
meaning to the respondent for the experienced
change, as well as by rating the degree of
importance the respondent assigns to
perceived change. In evaluation of
intervention-related change in evaluation
studies, the importance assigned to the small
improvement in one item of a domain of HRFS
may outweigh a moderate deterioration in
another item belonging to the same domain. 
Finally, the following are key issues in the
debate on methods for estimating clinically
important change: Significance of intervention
effects: "significance to whom
" [93], "who is to
say what is important?" [90] and "ask patients
what they want" [94, 118, 119, 120]
  have
increasingly become apparent. To give
clinically relevant meaning to change scores
gained on two different points in time using
HRFS instruments, several investigators
suggest that the current approaches could be
improved by taking more explicit account of
patients’ perceptions and expectations. A new
paradigm is incorporating individual patient
perspectives, expectations and preferences
with respect to the effects of (innovative)
interventions in the outcome measures. With
scoring systems based on individualised
measures such as the so-called Goal
Attainment Scale (GAS) or Patient Specific
Index (PCI), each patient essentially receives
his or her ‘own instrument’ and these
instruments seem to show an improved
sensitivity to change in health-related
functional status when compared with
conventional methods. [75, 92, 95, 121-125] 
Methodological studies focussed at improving
the longitudinal validity or responsiveness of
health outcome measurement should be aimed
at supporting, health professionals,
investigators and administrators in the
understanding and critical evaluation of the
appropriateness of health status measures and
understanding of methods in estimating and
interpreting change in patient-assessed health
outcomes. Health professionals increasingly
stress that in the realisation of effective care
and expected outcome of planned change in
the process of care delivery, patients’
preferences are essential sources of
information. The operationalisation of the
patient’s perception of the severity of limitation
in domains of health-related functioning, or
operationalisation of individual preference or
weighted relevance of items of health-related
functional status measures is still in its infancy.
However, for health administrators and
decision-makers, investigation into the validity
of patient-specific HRFS instruments used to
evaluate the outcomes of innovations in care,
standardisation of methods is required. HRFS
instruments cannot be used in the evaluation
of treatment and care without a valid way of
ascertaining what change in measured
difference scores means. 
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APPENDIX
Given Cohen’s formula 1 for the Effect Size index for means from matched samples:
where:
and assumed equal variance, i.e.:
(A2) gives:  
and for the Effect Size index for means of independent samples the standardizing unit is:
where:
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Now from equation A2 and A3 we use the difference between the standardizing unit for difference in
means for matched samples (SRM) being σ √2(1-r)/σ = √2(1-r) as large as would be in the case of
independent samples (ESP) 
26, p.48-52. Now we can subsitute SRM into ESP by:
we note that r is estimated in cases in which the standard deviation at baseline, outcome, as well as
the standard deviation of the difference or change score were published:
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